Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 3, 2026

Stock market today: Dow plunges over 1,000 points, S&P 500 and Nasdaq sink as oil surges amid war worries

View original at finance.yahoo.com
Stock market today: Dow plunges over 1,000 points, S&P 500 and Nasdaq sink as oil surges amid war worries US stocks sold off on Tuesday after Israel and US jets launched new strikes on Iran, as the widening conflict stoked worries about a drawn-out regional war…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Target market share was at least flat during holiday quarter, pointing to slightly softer customer demand for the industry

    80% confidence

  • Best Buy expects first quarter same-store sales to return to growth, rising 1%

    80% confidence

  • US willing to deploy ground troops in Iran for whatever duration necessary

    80% confidence

  • Since 2009, S&P 500 has seen more than 30 pullbacks of greater than 5%, suggesting stocks can be resilient in face of bad news

    80% confidence

  • Markets will take initial cues from leaders running point on the war (Trump, Hegseth)

    80% confidence

  • Target should stay in penalty box and is a 'prove it' stock; investors should favor Walmart or Costco on pullbacks

    80% confidence

  • First quarter lift expected to banks' trading business from increased volatility across markets from Iran war

    80% confidence

  • Trump administration will roll out program to mitigate rising energy costs, hardest military hits on Iran yet to come

    80% confidence

  • 10% increase in crude oil prices typically raises core inflation by 4 basis points and headline inflation by 20-30 basis points

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com